Pharmacy Times Continuing Education„¢ (PTCE), a leader in continuing education for retail, health-system, managed care and specialty pharmacists, announces Ali McBride, Pharm.D., M.S., BCOP, FAzPA, FASHP, as the keynote speaker for the 2018 Directions in Oncology Pharmacy„¢ meeting. The meeting will take place on Saturday, Nov. 10, at the Crowne Plaza Times Square Manhattan in New York City.
We are honored to have Dr. McBride as our keynote speaker as he is a recognized leader in oncology pharmacy practice, said Jim Palatine, R.Ph., MBA, president of PTCE. During this meeting, clinical specialists, infusion, staff and specialty pharmacists will gain insight into ways they can improve the value of patient care and outcomes in oncology clinic, hospital and specialty pharmacy settings.
McBride is a clinical coordinator of hematology/oncology at The University of Arizona Cancer Center and a clinical assistant professor at The University of Arizona College of Pharmacy. As part of his professional service, he is currently the president-elect of the Association of Community Cancer Centers (ACCC). In addition to being a longtime ACCC member, he has been an active member of the American Society of Health-System Pharmacists (ASHP) and the Hematology/Oncology Pharmacy Association (HOPA). McBride has been working on oncology drug shortages and has testified on behalf of HOPA at the Food and Drug Administration Drug Shortage Workshop; presented on behalf of ACCC at the Washington, D.C., Congressional Session; and was an invited member of the ASHP Drug Shortage Stakeholders meeting.
McBride is also actively involved with biosimilar regulation and the pharmacoeconomic impact of biosimilars in the U.S. marketplace. He is currently a working group member for HOPA on its biosimilar committee. In addition, he also serves on the National Quality Forum Cancer Standing Committee. Throughout his career, he has published numerous articles on drug shortages, oral chemotherapy adherence, stem cell transplant and biosimilar implementation into the U.S. health care market. During his keynote address, McBride will delve into the future of oncology care, discussing emerging therapies in oncology, oral oncolytics, biosimilars on the horizon and the oncology care model.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Directions in Oncology Pharmacy„¢ is a one-day interactive educational regional meeting that addresses topics such as effective management therapies to improve outcomes in patients with chemotherapy-induced nausea and vomiting and prostate cancer, cancer immunotherapy in recurrent or metastatic head and neck cancer and pharmacists roles in managing immune-related adverse effects associated with immuno-oncology therapies. The programs format will allow attendees to learn how to coordinate care through inpatient, ambulatory and community settings.
These activities are supported by educational grants from Bristol-Myers Squibb; Celgene Corporation; Helsinn Therapeutics (U.S.), Inc.; and Merck Sharp & Dohme Corp.
For more information or to register, please click here.
About Pharmacy Times Continuing Education„¢
Pharmacy Times Continuing Education„¢ (PTCE) is a leader in continuing education for retail, health- system, managed care and specialty pharmacists. PTCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). PTCEs print, online and live CPE activities are designed to help improve the knowledge, competence and skills of pharmacists so that they are better prepared to provide the highest quality of pharmacy care to the patients they serve and to the physicians they assist as part of a multidisciplinary treatment/management team. To learn more about the educational activities sponsored by PTCE, visit https://www.pharmacytimes.org/.